CytoSorb hemoperfusion

DEVICE2 trials

Sponsors

MedaSorb Technologies, Inc, Radboud University Medical Center

Conditions

Acute Lung InjuryAcute Respiratory Distress SyndromeBlood PurificationHemoperfusionImmune DeficiencySepsis

Phase 3

Assessing the Effects of CytoSorb Hemoperfusion on the Development on Immunoparalysis

CompletedNCT04643639

Radboud University Medical CenterBlood Purification, Hemoperfusion, Immune Deficiency +1

Start: 2020-09-16End: 2022-10-19Updated: 2022-12-22

Unknown Phase

Efficacy Study of CytoSorb Hemoperfusion Device on IL-6 Removal in ARDS/ALI Patients With Sepsis

CompletedNCT00559130

MedaSorb Technologies, IncAcute Lung Injury, Acute Respiratory Distress Syndrome, Sepsis

Start: 2007-11-30End: 2011-06-30Target: 100Updated: 2011-06-07

Related Papers

CytoSorb hemoperfusion markedly attenuates circulating cytokine concentrations during systemic inflammation in humans in vivo.

2023-03-2162 citations